Friday, November 03, 2023
Noramco, a prominent global manufacturer of active pharmaceutical ingredients (API), with a specialization in controlled substances, has recently finalized the acquisition of the Cambrex Drug Product Business Unit, formerly recognized as Halo Pharmaceuticals. This strategic acquisition is set to provide expanded service options for Noramco's API customers and its subsidiary, Purisys. These additional services encompass drug product formulation development, clinical and commercial drug product manufacturing, and packaging, available at facilities located in Mirabel, Québec, and Whippany, New Jersey. Noramco will also be returning to the use of the Halo Pharmaceutical brand as part of this acquisition.
Noramco, expressed his enthusiasm for this acquisition by stating, "This acquisition will enable Noramco to offer our customers an enhanced range of sourcing options, extending beyond APIs. With these additional capabilities, Noramco/Purisys clients can now engage in the development of drug product formulations for their APIs, catering to both clinical and commercial purposes. Having previously overseen the Halo Pharmaceuticals business, I have firsthand knowledge of the capabilities of both sites and am eagerly looking forward to collaborating with our existing and future customers. Additionally, we extend a warm welcome to nearly 400 new employees who are joining the Noramco family of companies."